Last week, Congress adopted comprehensive health care reform through the passage of the Patient Protection and Affordable Health Care Act (H.R. 3590) (signed into law on March 23) and the Health Care and Education Reconciliation Act (H.R. 4872) (signed into law on March 30) (together, the “Act”). The Act, which is estimated to bring an additional 32 million individuals into the health insurance market, brings significant challenges and opportunities to the pharmaceutical, biotechnology, and medical device industries.
Ropes & Gray will continue to monitor implementation of the Act in the coming months and will provide more in-depth analysis in separate alerts on specific topics of interest. See Ropes & Gray’s Health Reform Resource Center and specifically our Pharmaceutical and Device Industry section for all of the latest analyses and updates.
Below is a summary of the key elements of the Act that relate to the pharmaceutical, biotechnology, and medical device industries..
Please see full alert below for more information.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.
Topics: Affordable Care Act, Anti-Kickback Statute, Biosimilars, Biotechnology, False Claims Act, Federal Sentencing Guidelines, Healthcare, Medical Devices, Pharmaceutical, Sunshine Act
Published In:
Administrative Law Updates, Health Law Updates, Insurance Updates, Science, Computers & Technology Updates
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
© Ropes & Gray LLP | Attorney Advertising
